Progress in the exosomes mediating SARS-CoV-2 infection and transmission

doi:10.16352/j.issn.1001-6325.2023.04.0680

Abstract

Abstract: Exosomes play vital roles in the pathogenesis of COVID-19 infection. The infection and transmission of the disease is regulated by exosomes and their components, such as nucleic acids, proteins and other substances. The exosomes with COVID-19 particles are produced via the endosomal pathway from the infected cells, and mediate the viral infection and transmission to healthy cells, finally ending with the results of tissue damage and multiple organ dysfunctions. As the key mediators of intercellular communication, exosomes activate the immune system and enhance the response against virus invasion. In addition, COVID-19 may escape from immunity with the help of exosomes; this may be a potential way of reinfection. The role of exosomes in novel coronavirus infection and transmission provides important clues for the development of potential technology for the diagnosis and prevention.

Key words: exosomes, SARS-CoV-2, COVID-19

CLC Number:

R511

CUI Shiyu, ZHANG Haifeng. Progress in the exosomes mediating SARS-CoV-2 infection and transmission[J]. Basic & Clinical Medicine, 2023, 43(4): 680-684.

References

[1]Hassanpour M, Rezaie J, Nouri M, et al. The role of extracellular vesicles in COVID-19 virus infection[J]. Infect Genet Evol, 2020,85:104422.doi:10.1016/j.meegid.2020.104422.
[2]Yuana Y, Sturk A,Nieuwland R. Extracellular vesicles in physiological and pathological conditions[J]. Blood Rev, 2013, 27: 31-39.
[3]Théry C, Witwer KW, Aikawa E, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018):a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines[J]. J Extracell Vesicles,2018,7:1535750.doi:10.1080/20013078.2018.1535750.
[4]Ludwig AK,Giebel B. Exosomes: small vesicles participating in intercellular communication[J]. Int J Biochem Cell Biol, 2012, 44: 11-15.
[5]Hatmal MM, Alshaer W, Al-Hatamleh MAI, et al. Comprehensive structural and molecular comparison of spike proteins of SARS-CoV-2, SARS-CoV and MERS-CoV, and their interactions with ACE2[J]. Cells, 2020,9:2638.doi:10.3390/cells9122638.
[6]Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China[J]. N Engl J Med, 2020, 382: 1708-1720.
[7]Leng Z, Zhu R, Hou W, et al. Transplantation of ACE2 mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia[J].Aging Dis, 2020, 11: 216-228.
[8]Walls AC, Park YJ, Tortorici MA, et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycopro-tein[J]. Cell, 2020, 181:281-292.
[9]Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor[J]. Cell, 2020, 181:271-280.
[10]Pironti G, Andersson DC,Lund LH.Mechanistic and therapeutic implications of extracellular vesicles as a potential link between Covid-19 and cardiovascular disease manifestations[J]. Front Cell Dev Biol,2021,9:640723.doi:10.3389/fcell.2021.640723.
[11]Barberis E, Vanella VV, Falasca M, et al. Circulating exosomes are strongly involved in SARS-CoV-2 infection[J].Front Mol Biosci,2021,8:632290.doi:10.3389/fmolb.2021.632290.
[12]Hong W.Combating COVID-19 with chloroquine[J]. J Mol Cell Biol, 2020, 12: 249-250.
[13]Bansal S, Tokman S, Fleming T, et al. SARS-CoV-2 infection in lung transplant recipients induces circulat-ing exosomes with SARS-CoV-2 spike protein S2[J]. Clin Transl Med, 2021, 11: e576. doi: 10.1002/ctm2.576.
[14]Kalluri R,LeBleu VS. The biology function and biome-dical applications of exosomes[J]. Science, 2020, 367:eaau6977.doi: 10.1126/science.aau6977.
[15]Wang J, Chen S,Bihl J. Exosome-mediated transfer of ACE2 (angiotensin-converting enzyme 2) from endothelial progenitor cells promotes survival and function of endothelial cell[J]. Oxid Med Cell Longev,2020,2020:4213541.doi:10.1155/2020/4213541.
[16]Su G, Ma X,Wei H. Multiple biological roles of extracellular vesicles in lung injury and inflammation microenvironment [J]. Biomed Res Int, 2020, 2020: 5608382. doi:10.1155/2020/5608382.
[17]Ikhlas S, Usman A, Kim D, et al. Exosomes/microve-sicles target SARS-CoV-2 via innate and RNA-induced immunity with PIWI-piRNA system[J]. Life Sci Alliance, 2022, 5:e202101240. doi:10.26508/lsa.202101240.
[18]Wang Y, Zhu X, Jiang XM, et al. Decreased inhibition of exosomal miRNAs on SARS-CoV-2 replication underlies poor outcomes in elderly people and diabetic patients[J]. Signal Transduct Target Ther, 2021, 6:300.doi:10.1038/s41392-021-00716-y.
[19]Mishra R,Banerjea AC.SARS-CoV-2 spike targets USP33-IRF9 axis exosomal miR-148a to activate human microglia[J]. Front Immunol, 2021, 12: 656700. doi:10.3389/fimmu.2021.656700.
[20]Chutipongtanate S, Kongsomros S, Pongsakul N, et al. Anti-SARS-CoV-2 effect of extracellular vesicles released from mesenchymal stem cells[J]. J Extracell Vesicles, 2022, 11: e12201. doi:10.1002/jev2.12201.
[21]Song JW, Lam SM, Fan X, et al. Omics-driven systems interrogation of metabolic dysregulation in COVID-19 pathogenesis[J]. Cell Metab, 2020, 32:188-202.
[22]Balbi C, Burrello J, Bolis S, et al. Circulating extra-cellular vesicles are endowed with enhanced procoagulant activity in SARS-CoV-2 infection[J]. EBioMedicine, 2021, 67: 103369. doi:10.1016/j.ebiom.2021.103369.
[23]Ahmed S, Paramasivam P, Kamath M, et al. Genetic exchange of lung-derived exosome to brain causing neuronal changes on COVID-19 infection[J]. Mol Neurobiol, 2021, 58: 5356-5368.
[24]Saadaoui M, Kumar M,Khodor S. COVID-19 infection during pregnancy: risk of vertical transmission, fetal, and neonatal outcomes[J]. J Pers Med, 2021, 11:483. doi:10.3390/jpm11060483.
[25]Farkash EA, Wilson AM,Jentzen JM.Ultrastructural evidence for direct renal infection with SARS-CoV-2[J]. J Am Soc Nephrol, 2020, 31: 1683-1687.